PRACTICAL ONCOLOGY JOURNAL ›› 2013, Vol. 27 ›› Issue (4): 295-302.doi: 10.3969/j.issn.1002-3070.2013.04.002

• Articles • Previous Articles     Next Articles

The expression and significance of KAI1/CD82 and MRP1/CD9 in laryngeal squamous cell carcinomas

ZHANG Binghui1, FENG Jiapeng1, XING Wenyuan1, XU Xiuyu2, LI Xiaodan1, WANG Yu1   

  1. 1.Department of Otolaryngology/Head and Neck Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China;
    2.Department of Head and Neck Surgery, The Affiliated Tumor Hospital of Harbin Medical University
  • Received:2013-03-20 Online:2013-08-28 Published:2013-08-13

PDF (PC)

58

Abstract: Objective The expressions and significance of KAI1/CD82 and MRP1/CD9 in laryngeal squamous cell carcinoma(LSCC)were investigated.Methods Real-time quantitative PCR(Q-PCR)and immunohistochemical technique were employed to detect the expressions of KAI1/CD82 and MRP1/CD9 in the laryngeal tissues of 100 LSCC patients, randomly selected 30 cases of corresponding adjacent non-cancerous tissues as well as the influence of both proteins on the clinicopathological features and survival of LSCC patients.Results The changes in mRNA and protein expressions of KAI1/CD82 and MRP1/CD9 were consistent in two groups, and the expressions of KAI1/CD82 and MRP1/CD9 were significantly different among two groups(P＜0.01 or ＜0.05).The KAI1/CD82 and MRP1/CD9 expressions in patients with TNM stage Ⅲ~Ⅳ LSCC, poorly differentiated LSCC, clinical stage Ⅲ~Ⅳ LSCC or lymph node metastasis was markedly lower than that in those with TNM stage Ⅰ~Ⅱ LSCC, well differentiated LSCC, clinical stage Ⅰ~Ⅱ LSCC or no lymph node metastasis(P＜0.01 or ＜0.05).However, there was no marked difference in KAI1/CD82 and MRP1/CD9 expressions between males and females among patients in different age LSCC different parts and tissues(P＞0.05).In LSCC patients positive for KAI1/CD82 protein expression, the median survival time was 78 months, which was significantly longer than that in LSCC patients negative for KAI1/CD82 protein expression(48 months;χ2=6.98, P=0.008).In LSCC patients positive for MRP1/CD9 protein expression, the median survival time was 78 months, which was significantly longer than that in LSCC patients negative for KAI1/CD82 protein expression(49 months;χ2=5.45, P=0.02).Expression was positively correlated with KAI1/CD82 in LSCC and MRP1/CD9 protein(χ2=31.41, P＜0.01).Conclusion Both KAI1/CD82 and MRP1/CD9 are involved in the occurrence and development of LSCC, and may provide clinical information for evaluation of invasiveness, metastasis and prognosis of LSCC.Thus, KAI1/CD82 and MRP1/CD9 may serve as markers for determination of invasiveness, metastasis and prognosis of LSCC.

CLC Number: